Customer acquisition costs are soaring. Brokerage consolidation is accelerating. And the agencies that survive will be those that stop paying for volume and start bidding on probability.
There is a number that every independent Medicare agency knows but rarely says out loud: somewhere between 30 and 40 cents of every dollar spent on lead acquisition is wasted on prospects who will never enroll. It isn’t a rounding error. It’s a structural tax on every agency that buys leads by volume—and it’s compounding.
McKinsey’s analysis of the Medicare Advantage landscape confirms the pressure: member churn among MA beneficiaries has increased roughly 70% since 2017, and as brokers scramble during each Annual Enrollment Period to replace lost members and capture new ones, customer acquisition costs are soaring. That pressure is pushing smaller brokers out of the market entirely, while sending others searching for acquirers willing to absorb their books of business.
Source: McKinsey – The Future of Medicare Advantage (December 2024)
The casualties are already visible. In 2024, WTW sold its Medicare brokerage Tranzact at a $2.1 billion loss. Prudential shuttered Assurance IQ. SelectQuote projected it would sell 15% fewer Medicare Advantage plans because it could not afford to hire enough brokers. These weren’t marginal operators—they were well-capitalized enterprises that couldn’t make the unit economics work.
Source: Modern Healthcare – 2025 Medicare Enrollment Period Busier Than Usual for Brokers (October 2024)
To understand why agencies are drowning, follow the numbers through a single AEP cycle. A shared Medicare Advantage lead costs $40–55 during off-peak months. During the October–December AEP window, that price inflates 30–50%, pushing exclusive leads above $100. CMS has set the CY2026 Fair Market Value for initial MA enrollments at $694 in most states—the maximum an agent can earn on a first-year conversion.
Sources: CMS – CY2026 Agent/Broker Compensation Memo (June 2025) | Ritter Insurance Marketing – 2026 Broker Commissions (February 2026)
Now apply a realistic conversion rate. Industry data shows that shared leads convert at roughly 2–5%. At a $50 cost-per-lead and a 3% conversion rate, the effective cost-per-acquisition is $1,667—consuming the entire first-year commission of $694 and then some. An agency that buys 10,000 leads at $50 each spends $500,000. At 3% conversion, it enrolls 300 members and earns $208,200 in first-year commissions. That’s a $291,800 deficit before a single overhead dollar is counted.
The renewal tail—approximately $347 per member per year—eventually makes the math work, but only if the member stays enrolled. And here’s where churn delivers the second blow: with MA member switching rates up 70% since 2017, an increasing share of those renewals never materialize. The agency paid for the acquisition, the member switched plans, and the competitor collected the renewal.
Source: McKinsey – The Future of Medicare Advantage: MA Member Churn Data (December 2024)
The instinct of most agencies facing this math is to buy more leads, negotiate harder on price, or shift to higher-cost exclusive leads in search of better conversion. But this strategy treats the symptom while ignoring the disease. The disease is undifferentiated purchasing—buying every lead at the same price regardless of its actual conversion probability.
A March 2025 report from the Senate Finance Committee laid bare the scale of the problem. Insurer spending on agents’ and brokers’ fees and commissions nearly tripled from $2.4 billion in 2018 to $6.9 billion in 2023. Yet this massive increase in distribution spend hasn’t produced proportionally better outcomes—it has produced more aggressive marketing, more consumer complaints, and more regulatory scrutiny.
Source: Senate Finance Committee – “Pushing Medicare Advantage on Seniors” Report (March 2025)
The underlying problem is information asymmetry. Lead publishers know where and how they generated a lead. Buyers know nothing about that lead’s probability of converting until they’ve already spent the money. Every transaction is a bet made without data.
This is the problem RiskLync’s Sequential Intelligence Pipeline was built to solve—and it starts before the purchase is made.
ZipLync (Pre-Purchase): Before an agency commits a dollar, ZipLync assigns a conversion probability score to every lead using 3,000+ socioeconomic and behavioral attributes —a model that analyzes enrollment behavior patterns across 32,000+ ZIP codes. In validation, top-tier geographic tiers convert at 25x the rate of bottom-tier ZIPs. An agency receiving a list of 10,000 leads can immediately stratify that list by expected yield, allocating budget to the highest-probability prospects and declining or discounting the rest. This is the shift from buying leads to bidding on probability.
The ProLync Suite (Post-Purchase): Once high-value leads are acquired and additional PII becomes available, RiskLync’s Behavioral Scoring model go to work. ProLyncMA scores for general Medicare Advantage fit using 3,000+ socioeconomic and behavioral attributes. ProLyncC evaluates Chronic Special Needs Plan qualification—identifying leads with condition indication profiles that match C-SNP eligibility criteria. ProLyncD assesses Dual-Eligible Special Needs Plan eligibility, flagging prospects whose income and benefits profile indicates Medicaid-Medicare dual status probability. Each model routes leads to the product and the agent where conversion probability is highest.
In RiskLync’s retrospective Medicare study, agencies applying this sequential approach—geographic scoring before purchase, behavioral scoring after—achieved a 106% enrollment lift on the same lead budget. They didn’t buy better leads. They made better decisions about which leads to buy and where to route them.
Return to the agency spending $500,000 on 10,000 leads. With ZipLync pre-purchase scoring, suppose the model identifies 4,000 leads in the top three geographic tiers—where historical conversion rates average 8–12% instead of 3%. The agency concentrates its budget on those 4,000 leads, potentially at a higher per-lead cost of $75 each ($300,000 total), and uses the remaining $200,000 for additional high-tier prospects or reinvests in retention.
At an 8% conversion rate on 4,000 leads, the agency enrolls 320 members—more than the 300 it enrolled by buying 10,000 undifferentiated leads—while spending $200,000 less. When ProLync post-purchase filtering then routes each lead to the correct product (MA, C-SNP, or D-SNP), the product-match accuracy increases, agent time-per-enrollment drops, and first-year retention improves because members were matched to plans that actually fit their needs.
That’s how the 30–40% waste disappears. Not through cheaper leads. Through smarter decisions made at both stages of the pipeline.
Stop thowing away 30–40% of your lead budget. Request a ZipLync analysis of your AEP lead list and see which prospects are worth the bid—before you spend a dollar.